Showing results (221-230 of 259) with videos related to
Sort By:
Pageof 26
Toxicology and Applied Pharmacology|May 1, 1994
Role of metallothionein in carcinogenesisM G Cherian, S B Howell, N Imura, et al.The Journal of Clinical Investigation|November 1, 1990
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatinR D Christen, D K Hom, D C Porter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1985
High-dose cisplatin with sodium thiosulfate protectionC E Pfeifle, S B Howell, R D Felthouse, et al.Annals of Internal Medicine|December 1, 1982
Intraperitoneal cisplatin with systemic thiosulfate protectionS B Howell, C L Pfeifle, W E Wung, et al.American Journal of Surgery|November 1, 1994
A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancerK T Robbins, D Vicario, S Seagren, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cellsS Aebi, R Kröning, B Cenni, et al.Cancer Research|April 1, 1985
Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusionS Zimm, L J Ettinger, J S Holcenberg, et al.Cancer|July 15, 1994
A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignanciesE F McClay, P D Braly, S Kirmani, et al.Gynecologic Oncology|September 1, 1994
A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancerS Kirmani, P S Braly, E F McClay, et al.British Journal of Cancer|June 9, 1999
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatinB Cenni, H K Kim, G J Bubley, et al.Pageof 26